Biofrontera AG / / Ad hoc: Biofrontera AG: Distribution Agreement with Desitin for Ameluz® in Scandinavia . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Leverkusen, 6 February 2012 - Biofrontera Pharma GmbH, a fully-owned subsidiary of Biofrontera AG, has today signed an agreement with Desitin Arzneimittel GmbH, Hamburg, for the marketing and distribution of Ameluz® in Denmark, Sweden and Norway, with a preferred right of negotiation for Finland. Biofrontera receives a significant immediate down-payment and 35% of all of Desitin's net revenues with Ameluz®. Further details are made available in a parallel press release.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Contact:
Werner Pehlemann
Biofrontera AG
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
E-mail: w.pehlemann@biofrontera.com (mailto:w.pehlemann@biofrontera.com)
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
--- End of Message ---
Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany
WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Börse Düsseldorf;
